Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent

Seung-Woon Rha; Pramod K Kuchulakanti; Rajbabu Pakala; Edouard Cheneau; Jana A Fournadjiev; Ellen Pinnow; Afework Gebreeyesus; George Aggrey; Zuyue Wang; Augusto D Pichard; Lowell F Satler; Kenneth M Kent; Joseph Lindsay; Ron Waksman

doi:10.1016/j.amjcard.2004.06.065

Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent

Am J Cardiol. 2004 Oct 15;94(8):1047-50. doi: 10.1016/j.amjcard.2004.06.065.

Authors

Seung-Woon Rha¹, Pramod K Kuchulakanti, Rajbabu Pakala, Edouard Cheneau, Jana A Fournadjiev, Ellen Pinnow, Afework Gebreeyesus, George Aggrey, Zuyue Wang, Augusto D Pichard, Lowell F Satler, Kenneth M Kent, Joseph Lindsay, Ron Waksman

Affiliation

¹ Washington Hospital Center, Washington, DC 20010, USA.

PMID: 15476623
DOI: 10.1016/j.amjcard.2004.06.065

Abstract

Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.

Publication types

Comparative Study

MeSH terms

Anticoagulants / therapeutic use*
Drug Carriers / adverse effects*
Female
Heparin / therapeutic use*
Hirudins / analogs & derivatives*
Humans
Male
Middle Aged
Peptide Fragments / therapeutic use*
Recombinant Proteins / therapeutic use*
Retrospective Studies
Sirolimus / administration & dosage*
Stents / adverse effects*
Thrombosis / etiology*
Thrombosis / prevention & control*

Substances

Anticoagulants
Drug Carriers
Hirudins
Peptide Fragments
Recombinant Proteins
Heparin
bivalirudin
Sirolimus